Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunscreen TEAs Should Model Applications For Chronic-Use Cutaneous Drugs – FDA

This article was originally published in The Tan Sheet

Executive Summary

TEAs for UV filters should provide FDA with clinical safety data used to support approval of chronic-use cutaneous drugs and nonclinical testing should focus on potential long-term adverse effects, according to draft guidance required under the Sunscreen Innovation Act. FDA particularly is interested in comments about final formulation safety testing it anticipates requiring under specified monograph conditions.

Advertisement

Related Content

Manufacturers Argue FDA Sunscreen Reviews Keep Outside Science In Shade
Sunscreen Guidances Underscore FDA Standards Aren’t Changing
FDA Denies Remaining Sunscreen TEAs, Offers Primer On GRASE, Resources

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS108025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel